Healthcare Industry News: Biosense Webster
News Release - May 2, 2007
FDA Clearance Received for Heart Attack Stem Cell Clinical TrialPlatform stem cell technology now in two major US-based trials
MELBOURNE, Australia, May 2 (HSMN NewsFeed) -- Australia's adult stem cell company, Mesoblast Limited (ASX: MSB; US OTC: MBLTY), today announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or 'off-the-shelf', adult stem cells for patients with heart attacks.
The Phase 2 clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission. These showed that implantation of the company's proprietary allogeneic stem cells by catheter into damaged heart muscle resulted in significant improvement in heart function and reduction in congestive heart failure.
This clinical trial will be the first to test an allogeneic stem cell product injected by catheter into heart muscle damaged by a recent heart attack. The trial will use the latest generation catheters provided through Angioblast's ongoing relationship with the Johnson & Johnson companies, Cordis Corporation and Biosense Webster.
The commercial strategy for both Mesoblast and Angioblast is to generate high margin stem cell products that are obtained from a single donor, expanded, frozen, and subsequently used in thousands of unrelated, or allogeneic, recipients at the time and place of need.
Over one million new patients with heart attacks are treated annually in the US alone, representing a multi-billion dollar market opportunity. Current therapies do not result in rebuilding of heart muscle, and do not prevent progression of congestive heart failure, poor quality of life, and long-term deterioration.
Source: Mesoblast Limited
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.